Remote Jobs at Stoke Therapeutics

Stoke Therapeutics

201 - 500 employees

Founded 2017

🧬 Biotechnology

💊 Pharmaceuticals

🏥 Healthcare

💰 $125M Post-IPO Equity - Stoke Therapeutics on 2024-03

Biotechnology • Pharmaceuticals • Healthcare

Stoke Therapeutics is a biotechnology company developing RNA-based therapeutics that increase protein production from a patient’s own genes to treat rare genetic diseases. Its TANGO (Targeted Augmentation of Nuclear Gene Output) platform uses antisense oligonucleotides to upregulate gene expression in haploinsufficiency disorders. Lead programs include STK‑001, an antisense therapy in development for Dravet syndrome (SCN1A haploinsufficiency), and other programs focused on genetic neurology and rare disease indications.